Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,270.00
(
-0.31%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
107.19
(
-0.27%
)
Bitcoin
76,734.00
(
-0.87%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jb_118 post# 129721

Friday, 10/28/2011 6:56:40 PM

Friday, October 28, 2011 6:56:40 PM

Post# of 257580
What you’re overlooking is that the overhang to MNTA’s share price from Teva’s Lovenox program is now essentially gone.

If by some chance Teva actually got FDA approval, MNTA’s lawsuit against Teva (which has already been filed) would likely play out in a manner similar to MNTA’s lawsuit against Amphastar.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today